The FDA granted an emergency use authorization for the products. Read More

A vaccine could be available for emergency use in early 2021, the company said. Read More

The company said that it suspended its exclusivity to enable a greater supply of the drug should additional trials or evaluations show it has potential in treating COVID-19. Read More

Sanofi is in a separate partnership with HHS for a recombinant, protein-based vaccine candidate. Read More

The test is designed to deliver results within four hours of a sample being received by a laboratory. Read More

“Our test will provide a highly accessible means for healthcare professionals to access laboratory quality results close in their office to aid in the decision to isolate, treat or dismiss potential carriers,” the San Diego company said. Read More

The company said significant validation will be needed before the test is made available to combat the pandemic. Read More